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ABSTRACT 
 
Brett Lovell Phillips: A Case Study on the Effects of Exercise on Muscle Cross-Sectional 
Area during Induction Chemotherapy for Acute Myelogenous Leukemia 
 (Under the direction of Dr. Claudio Battaglini) 
 
 While aggressive chemotherapy is standard for promoting complete remission in 
newly diagnosed acute myelogenous leukemia patients, treatment side effects impair 
post-cancer quality of life due in part to negative changes in body composition and 
increases in cancer-related fatigue. This population would greatly benefit from an 
intervention which increases physical activity during treatment. Therefore, the primary 
purpose of this study was to examine the effects of aerobic and resistance exercise on 
muscle cross sectional area and fatigue before and after induction chemotherapy. One 
patient with acute myelogenous leukemia participated in this study. The exercise protocol 
included 30-40 minutes of aerobic and resistance exercise performed 2-4 days per week, 
twice a day for 4 weeks. While a decrease in vastus lateralis cross sectional area was 
present post-intervention, this decrease may have been much greater without the 
intervention. A decrease in self-reported fatigue was recorded. In conclusion, the results 
of this study suggest that an exercise intervention during induction chemotherapy may 
mitigate large losses in muscle cross sectional area and may potentially reduce fatigue. 
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CHAPTER I 
 
INTRODUCTION 
 
Acute myelogenous leukemia (AML) is one of the four major subgroups of 
leukemia and is estimated to represent 36% of the leukemia total in the US for 2014 
(American Cancer Society, 2014). Leukemia, in most simple terms, is a blood cancer. 
Depending on the leukemia subtype, immature or differentiated cells in the bone marrow 
and/or blood acquire a DNA mutation and the cells uncontrollably replicate. During this 
uninhibited cycle of abnormal cell replication, a crowding out of normal blood forming 
stem cells commonly manifests into pancytopenia (Roboz, 2012). Consequently, clinical 
issues that arise from the decreased red blood cell (RBC), white blood cell (WBC), and 
platelet counts may include but are not limited to the development of anemia, fatigue, 
increased susceptibility to infection, and a higher likelihood to bruise and bleed (Roboz, 
2012).  
The incidence per year of AML in the US in 2014 is estimated at 18,860 and has 
remained constant over the last three decades (Surveillance and Epidemiology End 
Results [SEER], 2012). The causes of most cases of leukemia are not understood; 
however, high doses of radiation and certain cancer therapies are possible causes 
(Rubnitz, Gibson, and Smith, 2010). Specifically for AML, repeated exposure to the 
chemical benzene may play a large role (Khalade et al., 2010). Benzene is found in 
automobile exhaust, industrial emissions, and exposure to tobacco smoke.  
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Due to the AML’s rapid progression, upon diagnosis, patients are immediately 
treated with seven days of an initial chemotherapy known as induction chemotherapy. 
These patients are given 3-4 weeks to recover in an in-patient hospital setting. The goal 
during this time is to bring the disease into remission, meaning less than five percent of 
leukemia cells remain in the bone marrow (Anderson et al., 2002). Standard of care for 
these patients during this time includes bed rest in the hospital room with all healthcare 
providers following strict neutropenic procedures in order decrease the risk for infection.  
The second phase of chemotherapy is the consolidation phase where all of the 
remaining leukemia cells are destroyed (Hiddemann et al., 1999). Even with 
chemotherapy and standard precautions, mortality for 2014 is estimated at 10,460, and 
data from 2003-2009 places five-year relative survival rate at only 24.9%-the lowest of 
the four subgroups of leukemia. 
While chemotherapy for AML improves overall patient survival; its use is 
accompanied by side effects that negatively alter many physiological systems; one such 
system affected is the musculoskeletal system via alterations in body composition (Al-
Majid and McCarthy, 2001; Hemming and Maher, 2005). Negative changes in body 
composition, i.e., increased percent body fat (%BF), decreased percent lean body mass 
(%LBM) and muscle wasting are common side-effects that impact physical function and 
often lead to a decrease in overall physical activity further impacting the overall 
physiology of the patient. The muscle wasting commonly observed in the cancer 
population can lead to lower physical function, impaired ability to perform activities of 
daily living, and lower quality of life (Basaria et al., 2002; Kyrdalen et al., 2010; Levy et 
al., 2008; Saigal, et al., 2007; Tsai et al., 2007). 
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The positive effects of exercise on body composition, cardiorespiratory fitness, 
muscular fitness, fatigue and overall quality of life in cancer patients have been 
evidenced primarily in patients with prostate, breast, and lymphoma cancer (Courneya, 
Segal, Mackey et al., 2007; Galvao et al., 2010; Milne et al., 2009; Vallance et al., 2005). 
Standard exercise prescriptions for this cancer populations have not yet been established, 
such that protocols continue to shift between aerobic only (Chang et al., 2008), resistance 
training only (Galvao et al., 2006; Hanson et al., 2013; Newton et al., 2009; Segal et al., 
2003; Segal et al., 2009) and resistance training + aerobic training (Alibhai et al., 2012; 
Battaglini et al., 2009; Courneya et al., 2007; Galvao et al., 2010; Klepin et al., 2011; 
Milne et al., 2008). The preponderance of strength training in exercise and cancer studies 
suggests the importance of preventing and/or attenuating the chemotherapy related side 
effects on skeletal muscle.  
Even though a combination of aerobic and resistance training has been shown to 
improve body composition in cancers such as breast and prostate (Galvao et al., 2010), 
studies examining the effects of exercise in acute leukemia are scarce. The nature of this 
disease with its detrimental impact on red blood cells, white blood cells, and platelets 
have warranted caution from exercising these hematological and immunologically 
compromised patients; however, the debilitating toll of this disease progression on body 
composition, physical function, and quality of life precludes this population as one that 
may most benefit from an exercise intervention.  
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Statement of Purpose 
The primary purpose of this study was to examine the effects of aerobic and 
resistance exercise on muscle cross sectional area and fatigue before and after induction 
chemotherapy. One patient with acute myelogenous leukemia participated in this study 
Definition of Terms 
Acute Myelogenous Leukemia: AML is a rapidly progressing blood cancer that starts in 
the bone marrow by developing from blood-forming stem cells. These immature cells 
build up in the marrow and blood, and spread quickly to other parts of the body. 
Induction Chemotherapy: The first phase of chemotherapy including seven days of 
intense chemotherapy with the goal of reaching remission (<5% leukemia cells in the 
bone marrow). Most often, patients undergo the standardized “7+3” regimen including 
seven days of Cytarabine, with added doses of an anthracycline on days 1-3. Following 
this regimen, patients remain in the hospital to recover for 3-4 weeks. 
Consolidation Chemotherapy: The second phase of chemotherapy with the goal of 
destroying any remaining leukemia cells. Frequently requiring 5 days in the hospital, 3 or 
more cycles of high-dose Cytarabine are given. 
Cancer Cachexia: Defined as “a multifactorial syndrome defined by an ongoing loss of 
skeletal muscle mass (with or without fat mass) that cannot be fully reversed by 
conventional nutritional support and leads to progressive functional impairment” (Fearon 
et al., 2011).  
Muscle Cross-Sectional Area (mCSA): The area of the cross section of a muscle belly, 
normally measured at its largest point.  
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Limitations 
1. Case study (n=1) limits generalizability. 
2. Limited recruitment within UNC medical system, physician referral. 
3. Different types of treatment could interfere with the study results. 
4. Low platelet count, fever, and low motivation resulted in deviations from the 
proposed scheduled exercise protocol. 
Delimitations 
1. Subject is recruited from the Leukemia unit of Lineberger Comprehensive Cancer 
Center at UNC-Hospitals. 
2. Confirmed new diagnosis of AML by pathology report. 
3. Subject is at least 21 years of age. 
4. Subject participates in two exercise sessions per day, 3-4 days per week for 4 
weeks. 
Assumptions 
1. The impact of varied anti-cancer treatment regimens and prophylaxis 
medications results in similar side effects experienced by patients.  
2. Subject adhered to the training protocol. 
3. Subject did not modify diet or exercise beyond what was prescribed during the 
study. 
Significance of the Study 
 The side effects of the anti-cancer treatments in acute leukemia are harmful to 
physiological health, overall functionality and quality of life (QOL). Each of these 
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aspects can lead to the development of other co-morbidities, which can also have a 
tremendous negative effect on the overall functionality, QOL, and survival time of the 
patient. Exercise is an intervention that has shown in other cancer populations to alleviate 
many negative effects of treatment, allowing patients to lead a healthier, higher 
functioning, and more active lifestyle.  
Patients with AML are undergoing rapid, intense treatment with the goal of 
stopping cancer progression, swiftly destroying cancer cells, and thus prolonging survival 
by achieving a sustained complete remission. Unfortunately, side-effects of anti-cancer 
treatments such as muscle wasting significantly impact patient ability to carry on 
activities of daily living, while increasing risk for development of other co-morbidities. 
These are all factors that have been shown to negatively impact the overall quality of life 
of this patient population.  
Most studies that have examined the effects of exercise in cancer patients have 
focused on early stage, solid tumor cancers such as breast and prostate with little research 
in patients with rapid advancing hematologic cancers. The loss of lean body mass in these 
patients illustrates one crucial variable in the multi-factorial development of cancer-
related fatigue. This fatigue further compromises recovery, QOL, tolerance to treatment, 
and perpetuates a further decrease in physical activity. The down spiral of events likely 
leads to greater fatigue and poorer outcomes. Therefore, it is paramount that studies 
examining the effects of exercise on different physiological, physical function, and its 
impact on overall quality of life and survival are conducted in this specific leukemic 
population.
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CHAPTER II 
 
REVIEW OF THE LITERATURE 
 
 Cancer is the second leading cause of death in the United States, following heart 
disease (Siegel et al., 2014). The lifetime probability of being diagnosed with cancer is 
slightly higher in men (45%) than women (38%). While it is projected that 1.6 million 
cases will be diagnosed in 2014, incidence rates are decreasing for all four major cancer 
sites, with the exception of female breast. Furthermore, cancer death rates are steady 
decreasing at slightly less than 2% per year according to the recorded data from 2005-
2009 (Siegel et al., 2014). 
 Modern medicine, coupled with the decreasing mortality rate, suggests that more 
individuals are successfully living longer with a prior diagnosis—either through 
remission or more effective care. Chances of survival increase when diagnosis is early, 
effective primary treatment is prescribed, and proper secondary treatments and therapies 
are used to encourage better overall quality of life (Smith et al., 2013). This has been 
evidenced in many cancers, including leukemia.    
For the purpose of organization, this literature review is divided into the following 
sections: 1) Leukemia Overview, 2) AML Treatment-Related Side Effects, 3) Exercise as 
Cancer Therapy, 5) AML and Exercise as a Treatment. 
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Leukemia Overview 
All cancer stems from the rapid, uncontrolled growth of abnormally functioning 
cells (Poste, 1980). Cancer arises as a consequence of DNA damage intertwined with 
errors in proper cell cycle behavior. The human body habitually produces these 
abnormally functioning cells; however, safety and repair mechanisms of the genetic cell 
cycle serve to either correct cellular irregularity or to ensure a discontinuation of cell 
specific growth. If both cellular missteps occur in concert, the irreparably damaged DNA 
will replicate and divide rapidly in one part of the body—resulting in site-specific tumor 
growth, or blood cell dysplasia if cancers of the bone marrow and/or blood. With the 
onset of metastasis, survival rates for all cancers decrease dramatically (Siegel et al., 
2013). 
Hematological cancers such as leukemia, myeloma, Hodgkin and non-Hodgkin 
lymphoma are the most common. Through their inference with the normal proliferation 
of blood cells, the risk of developing anemia, suffering from immunosuppression, and 
risk of bleeding/bruising each increase. In the United States, an estimated, 1.1 million 
people are living with or are in remission from one of these four hematological cancers 
and are expected to account for 9.4 percent of the estimated 1.7 million new diagnoses of 
cancer in 2014 (SEER). Depending on the specific cancer, five-year survival ranges from 
very poor (acute leukemia) to moderately-high (Hodgkin lymphoma). Overall, deaths 
from these are estimated at 55, 350 for 2014 (Cancer Facts & Figures, 2014).   
Survival for this population is fulfilled via intensive, immediate courses of 
chemotherapy to resist the cancer prior to metastasis. While chemotherapy may lead to 
remission in this population, the side effects may severely jeopardize the ability for 
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patients to continue normal activities of daily living at the same pace as pre-cancer levels-
ultimately leading to an established “new-normal.” Consequently, chemotherapy over 
time can become less effective leading to the need for higher doses and therefore 
decreasing the likelihood of a prolonged survival.  
AML Treatment-Related Side Effects 
While chemotherapy improves survival rate, compromised physiological health 
status is commonly reported as a result of treatment related side effects. One such 
example of impaired recovery is revealed through the deleterious effects on body 
composition parameters frequently observed corresponding with chemotherapy for acute 
leukemia. Overall, about one half of all cancer patients experience cachexia (Tisdale, 
1999).  Patients who experience a greater than 15% weight loss are likely to present with 
reduced respiratory muscle function, likely a major contributor to reduced survival time 
(De Wys et al., 1980).  
For newly diagnosed acute leukemia, one study noted that between weeks 4 and 6 
of chemotherapy, children showed a 27% decrease in femoral quadriceps muscle 
thickness measured using ultrasound ((Koskelo, Saarinen, and Siimes, 1990). Weight loss 
and subsequent decreases in lean body mass are commonly a result of a decreased food 
intake and/or increased energy expenditure; however, a likely additional mediator of the 
skeletal muscle wasting is the decrease in physical activity due to cancer-related fatigue. 
A multitude of studies address fatigue as one of the most prominent complaints of cancer 
patients. In over 60% of cancers, fatigue is manifested as a persistent, distressing 
symptom (Curt et al., 2000).  
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Because fatigue is in most cases not an immediate concern of treatment for an 
aggressive cancer such as acute leukemia, it may be inappropriately managed if managed 
at all. It is suggested that cancer-related fatigue negatively impacts health related QOL, 
activities of daily living, and body composition. This is especially the case in acute 
leukemia where the transition into complete remission through an immediate 
chemotherapy regimen is the primary concern. The fatigue resulting from the 
chemotherapy via complicated, multifactorial processes then leads to an increase in 
physical inactivity (Vermaete et al., 2014). Concurrently, due to low blood counts 
commonly observed in these patients, during their hospital stay, AML patients are 
confined to their room and must follow strict instructions to minimize the risk of 
infection. This environment naturally leads to additional physical inactivity, fatigue, and 
decreasing physiological fitness. 
When changes in body composition occur in these patients throughout treatment 
and for years after, co-morbidities are likely to develop. Several studies have addressed 
the issue of declining muscle mass on strength in cancer patients (Al-Majid and 
McCarthy, 2001; Hemming and Maher, 2005). Researchers compiled evidence showing 
that approximately 50% of persons with cancer battle significant progressive wasting of 
skeletal muscle and even contributes to declining tolerance and responsiveness to 
chemotherapy (Tisdale 1999; Van Eys, 1982). In a healthy, adult population, 
deconditioning via a decrease in muscle mass leads to premature fatigue. Similarly, in the 
cancer population, muscle wasting has been shown to be related to an exasperation of the 
multifactorial fatigue process (Dimeo et al., 1999).  
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Exercise as Cancer Therapy  
Historically, oncologists have advised cancer patients to rest and avoid physical 
exertion. This prescription of “physical inactivity” poses an obstacle for physiological 
fitness due to the treatment related side effects of cancer therapies; however, mounting 
evidence exists in favor of the efficacy of exercise in the cancer population for increasing 
factors of physiological health including fatigue (Dimeo et al., 1997; Mock et al,. 1997).  
While the physiological mechanisms are poorly understood in terms of increasing 
resistance to fatigue, it is speculated that regular endurance training that increases 
muscular endurance which increasing oxidative capacity of the muscles. For instance, 
when stage I and stage II breast cancer patients were prescribed a 6-week, self-paced 
walking intervention for 20-30 minutes a day, self-reported fatigue was decreased (Mock 
et al., 1997). When in-hospital patients on high-dose chemotherapy for several cancers 
performed daily biking at 50% cardiac reserve for 30 minutes, again fatigue was reduced 
(Dimeo et al,. 1999).   
One of the first examples of exercise as therapy for non-solid tumor cancers 
occurred in 1999 when researchers applied treadmill walking at 80% cardiac reserve for 
30 minutes a day, 5 days per week for 6 weeks. For these in-hospital patients undergoing 
chemotherapy for non-Hodgkin’s lymphoma, self-reported fatigue was decreased (Dimeo 
et al., 1997).  In the AML population, Chang and colleagues randomized patients into a 
walking based exercise group and a standard of care group. From admission to discharge, 
the exercise group showed a decrease in fatigue, overall symptom distress, anxiety, and 
depression compared to the group (Chang et al., 2008). 
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These previous examples of exercise therapy are using endurance-based 
modalities of exercise as therapy for fatigue; however, since the wasting of the skeletal 
muscle contributes to weakness and fatigue, then resistance exercise may provide an 
effective modality for combating cancer-related fatigue. 
It is a widely held concept that resistance training creates an environment that 
increases muscle mass. At the cellular level, contracting muscle induced by weight 
training has been shown in a single bout of exercise to increase protein synthesis by 50-
60% (Wong and Booth, 1990). This physiological mechanism can be applied to the 
recovery of muscle mass from issues such as prolonged bed rest, aging, and cancer 
(Ferrando et al., 1997; Yarasheski et al., 1993). In these populations, muscle protein 
synthesis is reduced with a simultaneous increase in degradation (Tisdale, 1997). 
 In prostate cancer patients, Segal et al. prescribed 12 weeks of whole body 
progressive resistance training for 155 men with early stage and metastatic prostate 
cancer on ADT. A usual care group was used as a control. Training intensity was 
established at 60-70% of 1-RM for two sets of 12 repetitions three times per week. The 
exercise group experienced improved symptoms of fatigue (p=0.002), improved health-
related quality of life (p=0.001), and increased upper (p=0.009) and lower body muscular 
fitness (p<0.001) all compared to the non-exercise group (Segal et al., 2003).  
A longer intervention was recently completed that examined a 20-week resistance 
exercise protocol, serving as an extension of the work by Segal and colleagues (Galvao et 
al., 2006). With a group of similar prostate cancer patients, dramatic muscular strength 
and muscular endurance gains were comparable to that of resistance exercise in healthy 
men-even on testosterone suppression (Galvao et al., 2005).  These results provide strong 
13 
 
evidence for the efficacy of resistance exercise to recover musculoskeletal health specific 
cancers such as prostate. 
Due to the emerging research implicating exercise as a safe and effective during 
and after cancer treatments, in 2009, the American College of Sports Medicine released a 
set of generalized exercise recommendations for patients who wish to incorporate 
physical activity as cancer therapy (Schmitz et al., 2010). These recommendations were 
developed as an expansion of the 2008 Physical Activity Guidelines for Americans 
advocating 150 minutes of moderate-intensity exercise, 75 minutes of vigorous-intensity 
exercise, or an equivalent of both. This framework should also include two to three 
weekly sessions of strength training for major muscle groups (Physical Activity 
Guidelines Advisory Committee Report, 2008).  The consensus states that these 
recommendations are generally appropriate for cancer patients; however, modifications 
for individualized prescriptions should exist based on health status and treatments 
received, and cancer prognosis (Schmitz et al., 2010). 
AML and Exercise as a Treatment 
Until recently, research on the effects of exercise in AML patients has been 
virtually non-existent. The research is even scarcer when detailing the effects of 
resistance and aerobic exercise on muscle size and fatigue. This is not surprising since the 
primary treatment focus is to lengthen survival time for patients in this situation. 
However, in 2009, Battaglini et al, examined the feasibility and physiological effects of 
exercise during induction chemotherapy using a combination of endurance and strength 
training 3 days per week, twice daily for 30 minutes. While decrements in body 
composition were still observed, patients lost only an average of 1.5 kg of lean body mass 
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as opposed to the average 5-10 kg during the induction phase of chemotherapy (2009). In 
addition, significant reductions (p=0.009) in total fatigue scores from baseline to post 
exercise intervention were documented. Subsequently, in 2011, researchers out of Wake 
Forest University offered AML patients undergoing induction chemotherapy 12 sessions 
of strength, flexibility, and walking, 30-45 minutes per sessions for 2-3 weeks. This 
prospective, non-randomized study was delimited to older adults (>50 years old) and 
focused on determining feasibility and adherence to an in-hospital exercise program, as 
well as to measure health related QOL and self-reported physical well-being. While body 
composition and fatigue were not reported, other important results were obtained 
including improved health related QOL, self-reported physical well-being, and a trend 
towards lower depressive symptoms (Klepin et al., 2011).   
Most recently, Alibhai and others published results on a non-randomized, mixed 
modality exercise intervention on AML patients during induction chemotherapy. This in-
hospital, 30-45 minute, 4-5 days per week for approximately 4 weeks improved six 
minute walk distance and a trend towards lowered anxiety, fatigue, and global quality of 
life (Alibhai et al., 2012). In a healthy adult population, the relationship between lean 
body mass and levels of fatigue are clear; however, in an aggressive form of cancer such 
as AML, studies have not focused on the role of exercise on muscle mass and fatigue. An 
interventional therapy such as exercise that targets cachexia proactively rather than 
retrospectively may improve the cancer-treatment experience, hasten recovery, and 
improve overall QOL. 
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CHAPTER III 
 
METHODOLOGY 
 
The goal of this study was to examine the effects of a 4-week combined resistance 
and aerobic exercise intervention to improve muscle CSA and reduce cancer-related 
fatigue in patients undergoing induction chemotherapy for AML. The project design was 
a prospective, one-arm case study conducted at UNC Chapel Hill.  
Subject 
One subject with newly diagnosed AML was recruited via the treating physicians 
and a clinical research coordinator at the UNC North Carolina Cancer Hospital. This 
subject provided informed consent, HIPPA, and storage of specimens documentation 
according to IRB guidelines.  Participation in this study involved a higher level of risk 
compared to exercise regimens for the general population. For patients on chemotherapy 
for AML issues such as low RBCs commonly result in early fatigue. Low WBCs create 
an environment where personal protective equipment and sanitation of all exercise 
equipment is essential in minimizing the risk of infection. In addition, low platelets 
counts increase the likelihood for bruising and bleeding.  Given the potential risks 
involved, proper precautions were taken and this subject was screened for inclusion/ 
exclusion for participation in the study. The inclusion criteria was as follows: 
 New diagnosis of acute leukemia by a pathology report from the subject’s 
physician at UNC Hospital. 
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 An admission for induction chemotherapy within the previous 96 hours of +/- 4 
days from the initiation of induction chemotherapy. 
 An expected hospital stay of 3-4 weeks or longer 
 Participation approved by the physician directly responsible for this subject’s 
care while at UNC Hospital. 
 Willing and able to provide signed informed consent 
 Willing and able to complete study questionnaires 
 Ability to understand and speak English 
 
Participation in any exercise regimen involves potential risks; patients were therefore 
screened for exclusion based upon the following: 
 Active cardiovascular disease, acute or chronic respiratory disease, and/or acute 
or chronic bone/joint/muscular abnormalities compromising the ability to exercise 
 Another active malignancy 
 Dementia, altered mental status or any psychiatric condition prohibiting the 
understanding or rendering of informed consent. 
 Active bleeding, acute thrombosis, ischemia, hemodynamic instability, and 
uncontrolled pain. 
The subject’s exclusion would have been determined by review of the potential 
candidate’s medical history by physician and study coordinator on the research team. If 
through the review, any of the exclusion criteria were observed, the participant would 
have been excluded from the study. 
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Instrumentation 
Height and body weight were obtained from the subject’s most recent medical 
records via EPIC or nurse documentation. The vastus lateralis muscle (VL) CSA was 
measured using a portable B-mode panoramic ultrasound technology (GE Logiq e, 
Milwaukee, WI, USA) with a 10-MHz linear-array probe for the acquisition of axial-
plane images of the VL. 
For the intervention, a combination of aerobic exercise equipment including a 
recumbent bike and treadmill, resistance bands, and body weight exercises were used on 
the subject’s hospital floor (4-Oncology) and in the subject’s hospital room at UNC 
Cancer Hospital.  
Assessment Protocol 
Age, race, height, weight, percent body fat, VL muscle CSA, hand strength, leg 
strength, and cardiorespiratory fitness were recorded and/or measured upon enrollment 
into the study. The study timeline of events are presented in Figure 1.  
Figure 1. Timeline of Study Protocol Events 
 
 
 
Both fitness assessments were conducted on 4-Oncology and the subject’s 
hospital room at UNC Cancer Hospital. The assessments included a cardiopulmonary 
exercise test (CPET) for assessment of cardiopulmonary function, isokinetic 
dynamometry for maximal muscle strength of the leg extensor and forearm flexor 
C
O
N
S
E
N
T 
Exercise intervention (4 days/week) (AM+PM).  
Subject had fitness testing, demographics, clinical data, PROs, and 
blood samples 
Chart Abstraction throughout study 
Baseline                 Week 1        Week 2        Week 3        Week 4                 Post-Induction 
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muscles, B-mode panoramic ultrasonography for VL CSA, skinfold thickness for percent 
body fat.  
The measurement for VL CSA was performed after the subject was lying in a 
supine position on the bed for 20 minutes to allow for fluid shifts to occur (Berg et al., 
1993). The ultrasound CSA measurement was performed on the right VL via manual 
movement of the transducer slowly and continually from lateral to medial along an upper 
leg template suitable for the subject. The purpose of the template is to ensure precise 
measurement and reproduction of the same muscle area for the comparison of pre- and 
post-intervention CSA images. Great care was taken to divide pressure of the probe 
equally to the skin, diminishing potential compression of the muscle tissue. 
In the musculoskeletal mode of the device, gain and frequency were standardized 
in order to optimize image quality.  Depth was adjusted to ensure both deep and 
superficial fascia remained visible in the field-of-view.  A generous amount (1 - 2 oz.) of 
hypoallergenic water-soluble transmission gel was applied to the skin to reduce possible 
near field artifacts and to enhance acoustic coupling (Aquasonic 100, Parker 
Laboratories, Inc., Fairfield, NJ, USA).  LogicView™ software (General Electric 
Company, Milwaukee, WI, USA) was used to generate real-time panoramic cross-
sectional images of the muscles. Three scans were performed and an average of the three 
were recorded in order to reduce the likelihood of technician error. Following each scan, 
each image was reviewed to ensure appropriate image quality. If a scan did not produce a 
clean image of CSA, additional scans were performed.  
 All ultrasound-imaging analyses were performed using Image-J software (version 
1.46r, National Institutes of Health, USA). Prior to analysis, each image was individually 
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scaled from area in pixels to centimeters using the straight-line function. CSA of VLs 
was determined using the polygon function by selecting a region of interest that included 
as much of the muscle as possible without any surrounding fascia.   
Exercise Intervention 
The exercise intervention encompassed both aerobic training and strength training 
twice a day, four days per week for 4 weeks. The time allotment for each exercise session 
was approximately 30-40 minutes with one trained exercise specialist to monitor each 
session. This intervention began the day following the baseline exercise assessment. The 
exercise training is summarized in Figure 2.  
 
 
 
 
 
Figure 2. Standard Exercise Session Protocol 
While adaptations were made throughout the intervention in order to 
accommodate individualized physical limitation or training response, a progression of 
training was followed via recommendations from the American College of Sports 
Medicine for stimulating a training effect within interventions.  The aerobic exercise 
segment began at 50% of VO2peak and all attempts were made to progress the intensity of 
the aerobic training by the last week of hospitalization to 60% VO2peak. Initially, the 
subject was intended to complete 5 minutes of aerobic exercise with a progression to 15 
minutes by week 4. At that point, progression would be solely through intensity.  
3 minutes 
Strength Training 
Upper body (AM) and Lower body (PM) 
incorporating stretch bands and body weight 
exercises with progressive increases in 
repetitions and sets 
10-20 minutes 
Aerobic Exercise 
Progressive increase in duration and intensity 
over 4 weeks from a minimum of 5 min. at 50% 
VO2peak  to a maximum of 15 minutes at 60% 
VO2peak 
5-15 minutes 
20-40 minutes 
Stretching 
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On the first day during the strengthening exercises, the subject attempted each 
upper body exercise (wall push-up, low row, triceps extension, and a choice between 
lateral raises, front raises, or military press) and lower body exercise (modified squat, leg 
curl, leg extension, and standing calf raise) A rough estimate of intensity in terms of sets 
and reps were gathered with the primary focus on posture, form, and comfort. After the 
first day, the subject trained using the 12-6 maximum repetition methodology, 1-2 sets 
per exercise. A similar protocol in the exercise oncology literature has demonstrated 
improvements in body composition parameters and muscle hypertrophy (Galvao et al., 
2010); however, modifications in execution were made because of the subjectivity of 
stretch band training. For instance, to increase intensity if the subject exceeded 12 
repetitions, the exercise specialist would decrease the length of band to pull against or 
change to a thicker band. 
Statistical Analysis 
 Due to the nature of this project as a case study, pre- and post-exercise 
intervention assessment data are presented as change scores and percent change. No 
formal statistical analyses were performed. 
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CHAPTER IV 
 
RESULTS 
 
This patient was newly diagnosed with acute myelogenous leukemia recruited 
from the University of North Carolina Hospitals (UNC-CH Hospitals), division of 
Hematology/Oncology. This patient’s results are summarized in Table 1 below.  
Table 1- Subject Results 
Measure Pre-Intervention Post-
Intervention 
Δ Score % 
Change 
Age (years) 34 34 0 0 
Height (cm) 155 155 0 0 
Weight (kg) 69.8 64.9 -4.9 7 
BMI 29.1 27.0 -2.1 7 
VO2 (ml/kg*min) 21.8 14.7 -7.1 33 
6MWD (m) 420 399 -21 5 
(R) Leg Strength (kg)  28.8 26 -2.8 10 
% Body Fat 23.9 23.0 -0.9 4 
VL Muscle Cross Sectional 
Area (cm
3
) 
54.2 47.0 -7.2 13 
Fatigue Score 51.5 44.3 -7.2 14 
Exercise Sessions 
Completed 
22/34 (64.7%) 
 
 It was expected that there would be maintenance of muscle cross sectional area 
between the baseline (week 1) and the completion (week 4) of the exercise intervention. 
The method of measurement is the analysis of the panoramic ultrasound images using 
Image J. This method translates cross sectional area into cm
3
. An example of an image 
that has been analyzed can be found in Appendix III. Vastus lateralis mCSA can be 
located in Table 1. 
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 It was also expected that an increase in fatigue would be minimized between the 
beginning and the completion of the exercise intervention. The overall fatigue level was 
measured using the compiled T-Score from the PROMIS Fatigue SF-8a Scale, assessed at 
the beginning of induction chemotherapy and at the end of the exercise intervention 
(week 4). T-scores are produced by summing the scores for each answer choice and then, 
using a rubric, transforming the raw scores into standardized T-scores. For most PROMIS 
instruments, a T-score of 50 is the average for the US general healthy adult population 
with a standard deviation of 10. For example, on the fatigue measure, a score of 30 
describes a patient who is two SD below the mean (less fatigue than average). Table 1 
provides the T-scores for pre and post exercise intervention. 
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CHAPTER V 
 
DISCUSSION, CONCLUSION, AND RECOMMENDATIONS 
 
Introduction 
 The standard of care for most cancer patients, including newly diagnosed AML 
patients is chemotherapy. The commonly used induction chemotherapy treatment plan, 
“7+3,” consists of a combination of cytarabine and an anthracycline and is by far the 
most successful at producing complete remission; however, referencing the lower than 
average 5-year survival rate compared to most cancers, this treatment plan is still far from 
optimal. In addition, commonly reported treatment-related toxicities, declines in physical 
function, and impairment to overall QOL result in a less than optimal post-cancer “new-
normal.” There is a great need to develop interventions that can mitigate the body 
composition related side-effects of powerful chemotherapy drugs in order to prevent 
cancer-related fatigue. 
 In the present case study, a combination of aerobic and resistance exercise, 
performed at a moderate intensity was prescribed as a means of mitigating the losses in 
muscle cross sectional area and decrease the burden of cancer-related fatigue. This study 
is one of only a few to explore body composition related changed in the AML population  
and will provide a foundation to explore more effective methods of exercise that may 
improve the cancer experience during induction chemotherapy. The primary purpose of 
this study was to examine the effects of a 4-week combined resistance and aerobic 
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exercise intervention to improve muscle CSA and reduce cancer-related fatigue in 
patients undergoing induction chemotherapy for AML.   
 Maintenance of VL Muscle Cross Sectional Area 
 According to expectations, there would not be a difference between VL CSA 
from pre-induction to post-induction chemotherapy. The results of the ultrasound analysis 
showed a decline in CSA of approximately 13%. It is difficult to compare these results to 
other exercise interventions in this population because panoramic ultrasound technology 
has not been used in the literature to measure changes in muscle size in this population. 
However, when comparing percent decrease in CSA in this study (14%) and the percent 
decrease in lean body mass from baseline to post exercise intervention in Battaglini et al., 
(2%), the comparison suggests the this intervention did not stimulate the vastus lateral 
enough to prevent losses in muscle size (2009).  
 Many reasons may accompany why the results suggest cachexia exists post-
intervention. Primarily, the intervention may not have stimulated an environment where 
protein synthesis out performed protein degradation. Past research suggest that moderate 
intensity resistance exercise can increase protein synthesis by 50-60% (Wong and Booth, 
1990). In this intervention, the patient performed 22 sessions, however, none of which 
provided more resistance than would be provided by a stretch band or body weight. 
 Another interpretation may be that the intervention mitigated further decreases in 
muscle CSA. Future research should explore the normal CSA losses from pre-induction 
to post-induction in this population in order to more fully understand how exercise is 
affecting the muscle during chemotherapy.   
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 Decrease in Overall Fatigue 
 An important finding in this study was the reduction in fatigue levels from pre-
induction to post-induction chemotherapy. This result is similar to the decreases in 
fatigue levels detailed in Alibhai et al., (2012) and Battaglini et al., (2009). This case 
study only adds to the evidence that an exercise intervention may provide a relief from 
cancer-related fatigue in AML patients undergoing treatment. Not only is fatigue reported 
as the most common side-effect of chemotherapy, it is also related to many other co-
morbidities and physiological systems.  
 AML patients are confined to hospital rooms for on average 3-5 weeks for 
induction chemotherapy and the subsequent recovery. During this period, many 
precautions are taken such that the immunocompromised patients do not develop 
infections that may impair recovery or shorten survival time. Essentially, patients are 
given the prescription of bed rest, confinement, and consequently little to no physical 
activity. This inactivity only leads to further decrements in body composition, and the 
cycle of increasing fatigue continues. The results of this exercise intervention suggest that 
possibly a mix of aerobic and resistance exercise may help at combating this cancer-
related fatigue. 
 Conclusion 
 The common goal when treating AML is to reach complete remission and remain 
in complete remission. Unfortunately, the current chemotherapy regimens fail to maintain 
measures of body composition such as muscle CSA. The literature is clear that 
maintenance of lean muscle mass is important in mitigating fatigue. A few studies are 
showing that primary resistance and aerobic based exercise interventions during the 
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induction phase of chemotherapy are not only safe and feasible, but also effective at 
mitigating the large losses in body composition and reducing the fatigue burden. 
Outcomes of this type of experiment can lead to future hypothesis testing. 
 Recommendations 
 Based on the results of this study and present limitations, recommendations for 
future research in the area of cancer and exercise, specifically, acute leukemia include: 
1. The completion and analysis of the EQUAL randomized controlled study. 
This two arm study will allow for researchers to compare the change in 
muscle cross-sectional area from pre- to post-intervention with those 
patients participating in the normal standard of care. 
2. When creating a strength maintaining program in which success is 
measured by vastus lateralis cross-sectional area, more emphasis should 
be placed on exercises that stimulate this muscle. Examples of exercises 
include lunges, side lunges, squats, leg extensions. As patients enter this 
setting with fitness levels that are across the spectrum of health, intensities 
should be cautiously increased using dumbbells, or alternatively decreased 
using body weight or modifications. 
3. Developing a higher level of control and recording over unsupervised 
physical activity while in the hospital. Recording the number of steps per 
day through accelerometer technology such as FitBit™ may achieve a 
measure of control through comparison of steps per day between each 
arm. 
27 
 
4. The implementation of increased physical activity based nutritional 
counseling in addition to standard of care nutritional counseling may 
improve outcomes such as weight maintenance, percent body fat changes, 
and maintenance of muscle cross-sectional area. 
5. Providing leukemia patients with educational information in reference to 
the potential benefits of maintaining a moderate level of physical activity 
during treatment. Physical activity is a treatment choice that the patient 
has control over. Psychologically, this may potentially empower patients 
who feel powerless against the disease. 
6. After completion and analysis of the EQUAL trial, extend the duration of 
the program to include the consolidation phase of the treatment plan. 
Boundaries include lack of supervision and motivation while the patient is 
at home between induction and consolidation; however, if possible, this 
extension may promote further benefits for the acute leukemia population. 
7. The impact of the exercise intervention post-treatment should be recorded. 
Relevant long-term measures may include level of physical activity 
compared to pre-treatment and during treatment, disease recurrence, 
hospital re-admittance, and overall survivorship rates.     
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Study Advertisement Flier 
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APPENDIX II 
 
PROMIS Fatigue SF 8a 
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SCORING THE INSTRUMENT (PROMIS Fatigue SF 8a) 
 
Short Forms: PROMIS instruments are scored using item-level calibrations. This means 
that the most accurate way to score a PROMIS instrument is to utilize scoring tools 
within Assessment Center that look at responses to each item for each participant. We 
refer to this as “response pattern scoring.” Response pattern scoring tools within 
Assessment Center can be used even if data was collected on paper or in another software 
package. Because response pattern scoring is more accurate than the use of raw 
score/scale score look up tables, it is preferred. However, if you aren’t able to use 
response pattern scoring, you can use the instructions below which rely on raw 
score/scale score look-up tables. For adults, each question has five response options 
ranging in value from one to five. To find the total raw score for a short form with all 
questions answered, sum the values of the response to each question. For example, for the 
8-item form, the lowest possible raw score is 8; the highest possible raw score is 40 (see 
all short form scoring tables in Appendix 1).  
 
A score can be approximated if a participant skips a question. If items are missing, first 
check how many items were answered. For short forms with at least 5 items, confirm that 
4 or 50% of items, whichever is greater, were answered. For example, a 4-item short 
form can only be scored with complete data. A 5-item short form can be scored as long as 
4 items were answered. A 10-item short form can be scored as long as the participant 
answered at least 5 items. For branched instruments (e.g., Alcohol Use), the screening 
question is not used in calculating the score and therefore shouldn’t be counted when 
assessing if the minimum number of items were answered. After confirming that enough 
responses were provided, sum the response scores from the items that were answered (not 
including any screening question). Multiply this sum by the total number of items in the 
short form. Finally, divide by the number of items that were answered. For example, if a 
respondent answered 5 of 8 questions and answered all items with the second lowest 
response option (2), you would sum all responses (10), multiply by the number of items 
in the short form (8) and divide by the number of items that were answered (5). Here 
(10x8)/5=16. If the result is a fraction, round up to the nearest whole number. This is a 
pro-rated raw score.  
 
Again, the formula is: 
(Raw sum x number of items on the short form) / Number of items that were actually 
answered 
 
Locate the applicable score conversion table in Appendix 1 and use this table to translate 
the total raw score or pro-rated score into a T-score for each participant. The T-score 
rescales the raw score into a standardized score with a mean of 50 and a standard 
deviation (SD) of 10. Therefore a person with a T-score of 40 is one SD below the mean. 
It is important to note that Assessment Center will convert a participant’s pattern of 
responses to a standardized T-score after they have finished a CAT. The standardized T-
score is reported as the final score for each participant. 
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Important: A higher PROMIS T-score represents more of the concept being measured. 
For negatively-worded concepts like Fatigue, a T-score of 60 is one SD worse than 
average. By comparison, a Fatigue T-score of 40 is one SD better than average.  
 
PROMIS Fatigue SF 8a Scoring Table 
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APPENDIX III 
 
Panoramic Ultrasound Analysis Example Using Image-J 
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APPENDIX IV 
 
BORG Rate of Perceived Exertion (RPE) Scale 
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